Effects of commonly used medications on bone tissue mineralisation in SaOS-2 human bone cell line
| Autor: | Dalia Somjen, Oleg Dolkart, Sara Katzburg, Moshe Salai, Roy Gigi, O. Yakobson |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Serotonin reuptake inhibitor Osteoporosis Proton-pump inhibitor Citalopram Pharmacology Bone and Bones Cell Line Calcification Physiologic Internal medicine medicine Humans Hypoglycemic Agents Orthopedics and Sports Medicine Rosuvastatin Rosuvastatin Calcium Omeprazole Cell Proliferation Metoprolol Sulfonamides Osteoblasts business.industry Proton Pump Inhibitors medicine.disease Adrenergic beta-1 Receptor Antagonists Metformin Fluorobenzenes Pyrimidines Endocrinology Surgery Hydroxymethylglutaryl-CoA Reductase Inhibitors business Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | The Bone & Joint Journal. :1575-1580 |
| ISSN: | 2049-4408 2049-4394 |
| DOI: | 10.1302/0301-620x.95b11.31158 |
| Popis: | We analysed the effects of commonly used medications on human osteoblastic cell activity in vitro, specifically proliferation and tissue mineralisation. A list of medications was retrieved from the records of patients aged > 65 years filed in the database of the largest health maintenance organisation in our country (> two million members). Proliferation and mineralisation assays were performed on the following drugs: rosuvastatin (statin), metformin (antidiabetic), metoprolol (β-blocker), citalopram (selective serotonin reuptake inhibitor [SSRI]), and omeprazole (proton pump inhibitor (PPI)). All tested drugs significantly stimulated DNA synthesis to varying degrees, with rosuvastatin 5 µg/ml being the most effective among them (mean 225% (sd 20)), compared with metformin 10 µg/ml (185% (sd 10)), metoprolol 0.25 µg/ml (190% (sd 20)), citalopram 0.05 µg/ml (150% (sd 10)) and omeprazole 0.001 µg/ml (145% (sd 5)). Metformin and metoprolol (to a small extent) and rosuvastatin (to a much higher extent) inhibited cell mineralisation (85% (sd 5)). Our results indicate the need to evaluate the medications prescribed to patients in terms of their potential action on osteoblasts. Appropriate evaluation and prophylactic treatment (when necessary) might lower the incidence and costs associated with potential medication-induced osteoporosis. Cite this article: Bone Joint J 2013;95-B:1575–80. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|